Novavax has received $1.6 billion from the federal government to
complete late-stage clinical development, including a Phase 3 clinical
trial; establish large-scale manufacturing; and deliver 100 million
doses of NVX‑CoV2373, its COVID-19 vaccine candidate, as early as late
2020.
As part of Operation Warp Speed Regeneron Pharmaceuticals has received $450 million to make and supply its own COVID-19 vaccine candidate, REGN-COV2. The agreement supports continued manufacturing so that the product could be made available immediately in the US if clinical trials are successful and the US Food and Drug Administration grants Emergency Use Authorization or product approval.
Read more at:
Novavax receives $1.6 billion from US government for 100 million vaccines | Euronews
As part of Operation Warp Speed Regeneron Pharmaceuticals has received $450 million to make and supply its own COVID-19 vaccine candidate, REGN-COV2. The agreement supports continued manufacturing so that the product could be made available immediately in the US if clinical trials are successful and the US Food and Drug Administration grants Emergency Use Authorization or product approval.
Read more at:
Novavax receives $1.6 billion from US government for 100 million vaccines | Euronews
No comments:
Post a Comment